Kamada Discontinues AAT Trial After Futility Analysis, Reiterates 2025 Revenue Guidance of $178M-$182M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Globenewswire
- Trial Discontinuation: Kamada announced the discontinuation of its inhaled AAT trial based on an independent Data and Safety Monitoring Board's interim futility analysis, indicating a low likelihood of achieving statistical significance in the primary endpoint, although no safety concerns were identified.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million, indicating confidence in maintaining strong performance despite the disappointing trial results.
- Future Growth Outlook: Kamada projects double-digit growth in revenues and profitability for 2026, driven by its six FDA-approved specialty plasma-derived products marketed in over 30 countries and an expanding biosimilar portfolio.
- Business Development Strategy: The company is focused on pursuing new business development opportunities to support long-term growth, leveraging its strong cash position and existing commercial infrastructure to drive future market expansion and product development.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like KMDA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on KMDA
Wall Street analysts forecast KMDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMDA is 14.00 USD with a low forecast of 13.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.640
Low
13.00
Averages
14.00
High
15.00
Current: 8.640
Low
13.00
Averages
14.00
High
15.00
About KMDA
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.
Report Overview: Recent reports from investment and research firms provide insights into analysts' perspectives on various companies.
Disclaimer: The views expressed in these reports do not reflect the opinions or recommendations of Barron’s.
Investment Services: Some report issuers may have existing or potential investment-banking relationships with the companies analyzed.
Purpose of Reports: The reports serve as a sampling of analyst thinking rather than definitive investment advice.
Continue Reading
Kamada Forecasts $200M-$205M Revenue for 2026 with 13% Growth
- 2026 Financial Outlook: Kamada projects revenues of $200 million to $205 million for 2026, representing a 13% year-over-year increase based on the midpoint of 2025 guidance, highlighting the company's ongoing organic growth potential across its diverse product portfolio in the biopharmaceutical sector.
- Adjusted EBITDA Growth: The company anticipates adjusted EBITDA to reach $50 million to $53 million in 2026, reflecting a 23% increase from the midpoint of 2025, which signifies a substantial enhancement in profitability and boosts investor confidence.
- Strong Cash Position: Kamada expects to end 2025 with approximately $75 million in cash, ensuring financial flexibility for future investments and business expansions, thereby strengthening its competitive edge in global markets.
- Strategic Development Focus: The company will continue to prioritize new business development and M&A transactions to accelerate long-term profitable growth, a strategy that will enrich its marketed product portfolio and generate synergies with existing operations.
Continue Reading